<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Therapy related <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancy</z:e> of the hematological system is small but real risk after adjuvant chemotherapy for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It includes <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); however T-cell prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (T-<z:chebi fb="1" ids="53412">PLL</z:chebi>) has not been described earlier in relation to <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and its therapy </plain></SENT>
<SENT sid="2" pm="."><plain>T-<z:chebi fb="1" ids="53412">PLL</z:chebi> is a rare <z:hpo ids='HP_0011010'>chronic</z:hpo> T-cell <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> with a mature post-thymic T-cell immunophenotype and aggressive clinical course </plain></SENT>
<SENT sid="3" pm="."><plain>CASE PRESENTATION: A 45 year old Indian female of Nordic origin presented 5 years back with a lump in the right breast and the axilla </plain></SENT>
<SENT sid="4" pm="."><plain>She underwent modified radical mastectomy </plain></SENT>
<SENT sid="5" pm="."><plain>Histophotomicrograph of the excised breast lesion showed a 2.1 cm duct <z:mp ids='MP_0002038'>carcinoma</z:mp>, positive for ER and PR with 1 out of 25 lymph nodes positive for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>She received 6 cycles of chemotherapy with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="47898">epirubicin</z:chebi>, and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>This was followed by <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> 20 mg per day for five years </plain></SENT>
<SENT sid="8" pm="."><plain>She was doing well on follow up until the completion of fifth year of <z:e sem="disease" ids="C0017925" disease_type="Disease or Syndrome" abbrv="">her disease</z:e>, when she presented with complaints of mild <z:hpo ids='HP_0001945'>fever</z:hpo> and <z:mp ids='MP_0000746'>weakness</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Examination revealed generalized lymph node enlargement along with <z:hpo ids='HP_0002240'>hepatomegaly</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Hemogram showed mild <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:mpath ids='MPATH_458'>normal</z:mpath> platelet count and a leukocyte count of 1.2 x 10(11)/L </plain></SENT>
<SENT sid="11" pm="."><plain>Peripheral blood examination revealed medium sized lymphoid cells, constituting almost 75% of total nucleated cell population </plain></SENT>
<SENT sid="12" pm="."><plain>Immunophenotying, established a diagnosis of post thymic T-cell prolymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Contrast-enhanced computed tomography of the chest and abdomen was done which revealed an anterior <z:e sem="disease" ids="C0240318" disease_type="Disease or Syndrome" abbrv="">mediastinal mass</z:e> with destruction of sternum along with multiple small nodular shadows in bilateral lung fields suggestive of lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Fine needle <z:hpo ids='HP_0002835'>aspiration</z:hpo> cytology of the mass showed atypical ductal cells with nuclear pleomorphism, which were positive for ER, PR and Her2neu protein </plain></SENT>
<SENT sid="15" pm="."><plain>This confirmed a co-existent metastatic <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>She was started on chemotherapy for T-<z:chebi fb="1" ids="53412">PLL</z:chebi> along with hormonal therapy with <z:chebi fb="0" ids="50790">aromatase inhibitor</z:chebi> </plain></SENT>
<SENT sid="17" pm="."><plain>Unfortunately, both her <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> progressed after an initial stable disease of two months </plain></SENT>
<SENT sid="18" pm="."><plain>CONCLUSION: Our case describes the potential of breast chemotherapy to cause grave second <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> of the T-cell lymphoid lineage, not described earlier </plain></SENT>
<SENT sid="19" pm="."><plain>Such events highlight the importance to identify those patients of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> in whom chemotherapy can safely be avoided </plain></SENT>
</text></document>